MCAM and brain neoplasm: We also administered bemcentinib to mice that were intracranially inoculated with BrM-CSCs and found that bemcentinib significantly inhibited the growth and vascularization of brain tumors in vivo (Figure 6L and S5P), indicating that AXL signaling is indispensable for the overexpression of CD146 and its mediated angiogenesis.